Scientists Create Hepatitis Infection

July 24, 1997

St. Louis -- Scientists have infected animals with hepatitis C by inoculating them with copies of the virus's genetic material. The study, reported in the July 25 issue of Science, proves for the first time that the hepatitis C virus (HCV) alone is sufficient to cause the disease should aid in understanding this medically important virus.

"Although HCV was strongly linked to blood-transmitted hepatitis, it was still possible that an additional, unidentified agent was required for disease," says Charles M. Rice, Ph.D., head of the research team. "Our study essentially eliminates this possibility."

The researchers constructed differing sequences of the virus's ribonucleic acid (RNA) the genetic material of HCV and inoculated them into chimpanzees. This enabled them to identify the necessary elements for infection. The availability of unlimited quantities of this well-defined RNA will permit precise studies of how the virus turns itself into more virus. This information is essential to the development of better treatments for hepatitis C, the most common cause of liver failure in the United States.

Rice is a professor of molecular microbiology at Washington University School of Medicine in St. Louis. Research associate Alexander A. Kolykhalov, Ph.D., is lead author of the paper. Scientists at the U.S. Food and Drug Administration in Bethesda, Md., also played a pivotal role in the study.

Hepatitis C is a chronic disease that inflames the liver, producing fatigue and flu-like symptoms. The current therapy interferon fails to cure 80 percent of those infected. And about 20 percent of people with chronic HCV develop cirrhosis of the liver, which often leads to liver failure and, in some cases, liver cancer.

About 1 percent of the world's population is infected by HCV, though the rate may reach more than 10 percent in some countries. In the United States, the virus was the most common cause of transfusion-associated hepatitis before the development of screening tests for blood donors. It still spreads rapidly among intravenous drug users.

Wanting to define the exact genetic sequence that causes disease, the Washington University scientists derived copies of the RNA from a clinical sample of HCV. Like someone twirling a combination lock, they assembled overlapping pieces to create thousands of different clones. Screening these clones, Kolykhalov identified 34 that might cause infection.

Since the virus replicates poorly in cell cultures, FDA researchers Stephen Feinstone, M.D., and Kathleen Mihalik injected the 34 clonal RNAs into the livers of two chimpanzees, the only animal model for HCV infection. But neither chimp showed any sign of infection.

Rice's group then compared six of these clones to see which nucleotide occurred most often at each position. This consensus sequence on paper at that point matched none of the previously sequenced clones.

The researchers therefore constructed lengths of RNA with the consensus sequence to see if these would be infectious. They also made nine variants to include potentially important differences at or near the ends of the viral RNA.

The FDA researchers inoculated each of the 10 RNA sequences into different regions of a chimpanzee's liver. They used a different technique to inoculate lower doses into a second animal.

A week after inoculation, circulating viral RNA clearly was detectable in the animals' blood. In subsequent weeks, levels rose steadily. The animals' serum also developed markers for liver damage, and biopsies revealed signs of disease in parts of the liver that had received certain of the constructs.

"The contrast between these results and those from our failed experiments provided some of the strongest evidence that at least one of the inoculated RNA sequences was infectious," Feinstone says. And several tests confirmed that the circulating RNA was inside new virus particles and was not just inoculum leaked from the liver.

Because the researchers had tagged the different variants with silent changes in the genetic letters, they could determine which ones had proved infectious. The consensus strand alone turned out to be sufficient to cause disease.

The group now wants to compare animals that get rid of the virus with those that establish a long-lasting infection. "We need to know what kinds of immune responses eliminate the virus and how HCV manipulates the immune system if we're to develop effective vaccines or immunotherapies," Rice explains. "The ability to infect chimpanzees with a defined HCV sequence also provides an unprecedented opportunity for studying HCV evolution and the immune system's response."

The availability of this infectious sequence of RNA also will enable researchers to knock out HCV genes to see which are essential for replication. The products of such viral genes are attractive targets for the development of drugs such as protease inhibitors, which are so effective against HIV. "The lack of a genetic system for studying HCV replication was a real problem previously," Rice says.

Both Feinstone's group and Rice's group are transfecting various cells with the cloned RNA in hopes of developing cell culture models and alternative animal models, such as mice. These systems would enhance studies of the infectious process and be a boon to the pharmaceutical industry. Many companies are trying to develop better treatments for hepatitis C, but the lack of experimental systems for evaluating the effects of candidate drugs on HCV replication has hampered progress.

"The fact that interferon therapy works for at least 10 to 20 percent of patients tells you that hepatitis C is a curable disease," Rice says. "With better drugs, there's a reasonable chance we could control or perhaps eliminate this virus from the majority of people who are chronically infected."


How does hepatitis C differ from other forms of hepatitis?

Do blood transfusions still place people at risk of HCV infection?

How strong is the link between chronic HCV infection and liver cancer

How does the hepatitis C virus replicate inside liver cells?

Why were researchers uncertain about the composition of the HCV genome when the virus already had been cloned?

How did Rice and colleagues prove that the RNA they detected in the chimp blood was inside new viral particles and was not inoculum that had leaked out of the liver?


Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570-574, July 25, 1997. Grants from the National Institutes of Health supported this research.

Washington University School of Medicine

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to